Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Tauopathies

• Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
• A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population
• An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
• A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
• A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants
• Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
• Study to Assess the Efficacy of XPro™ in Patients With Mild Alzheimer's Disease With Biomarkers of Inflammation
• Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
• The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy
• BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES
• 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls
• A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
• Novel Neuroimage Study in Tauopathies With Parkinsonism
• Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
• Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
• A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects
• 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism
• Safety Study of TPI-287 to Treat CBS and PSP
• Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
• Davunetide (AL-108) in Predicted Tauopathies - Pilot Study